Abstract
Sinusoidal obstruction syndrome (SOS) is a serious complication of hematopoietic stem cell transplantation (HSCT). Sirolimus plus tacrolimus is an accepted regimen for graft-versus-host disease (GVHD) prophylaxis, with both agents implicated as risk factors for SOS. We analyzed 260 consecutive patients who underwent allogeneic HSCT following myeloablative conditioning using total body irradiation (TBI)-based (n = 151) or chemotherapy only (n = 109) regimens, with sirolimus plus tacrolimus for GVHD prophylaxis. SOS occurred in 28 patients at a median of 22 (range, 12–58) days. Mean sirolimus trough levels were higher between days 11 and 20 following transplant in patients who developed SOS (10.3 vs. 8.5 ng/ml, P = 0.008), with no significant difference in mean trough levels between days 0 and 10 (P = 0.67) and days 21–30 (P = 0.37). No differences in mean tacrolimus trough levels during the same time intervals were observed between those developing SOS and others. On multivariable analysis, a mean sirolimus trough level ≥ 9 ng/ml between days 11 and 20 increased the risk of SOS (hazard ratio 3.68, 95% CI: 1.57–8.67, P = 0.003), together with a longer time from diagnosis to transplant (P = 0.004) and use of TBI (P = 0.006). Our results suggest that mean trough sirolimus levels ≥ 9 ng/mL between days 11 and 20 post transplant may increase the risk of SOS and should be avoided.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157–68. https://doi.org/10.1016/j.bbmt.2009.08.024. e-pub ahead of print 2009/09/22.
Carreras E, Diaz-Beya M, Rosinol L, Martinez C, Fernandez-Aviles F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl. 2011;17:1713–20. https://doi.org/10.1016/j.bbmt.2011.06.006. e-pub ahead of print 2011/06/29.
Girinsky T, Benhamou E, Bourhis JH, Dhermain F, Guillot-Valls D, Ganansia V, et al. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol. 2000;18:981–6. https://doi.org/10.1200/JCO.2000.18.5.981. e-pub ahead of print 2000/03/01.
Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transpl. 2002;8:493–500. https://doi.org/10.1053/bbmt.2002.v8.pm12374454. e-pub ahead of print 2002/10/11.
Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol. 2004;11:386–91. https://doi.org/10.1097/01.moh.0000143701.88042.d9. e-pub ahead of print 2004/11/19.
Cutler C, Antin JH. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transpl. 2004;34:471–6. https://doi.org/10.1038/sj.bmt.1704604. e-pub ahead of print 2004/07/27.
Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109:3108–14. https://doi.org/10.1182/blood-2006-09-046219. e-pub ahead of print 2006/12/02.
Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115:1098–105. https://doi.org/10.1182/blood-2009-03-207563. e-pub ahead of print 2009/12/08.
Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124:1372–7. https://doi.org/10.1182/blood-2014-04-567164. e-pub ahead of print 2014/07/02.
Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425–31. https://doi.org/10.1182/blood-2008-07-169342. e-pub ahead of print 2008/09/09.
Kiel PJ, Vargo CA, Patel GP, Rosenbeck LL, Srivastava S. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation. Pharmacotherapy. 2012;32:441–5. https://doi.org/10.1002/j.1875-9114.2012.01034.x. e-pub ahead of print 2012/04/14.
Morishita T, Okabe M, Kawaguchi Y, Lee Y, Ohbiki M, Osaki M, et al. Higher peak tacrolimus concentrations after allogeneic hematopoietic stem cell transplantation increase the risk of endothelial cell damage complications. Biol Blood Marrow Transpl. 2018;24:2509–16. https://doi.org/10.1016/j.bbmt.2018.07.029. e-pub ahead of print 2018/07/28.
Farag SS, Srivastava S, Messina-Graham S, Schwartz J, Robertson MJ, Abonour R, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22:1007–15. https://doi.org/10.1089/scd.2012.0636. e-pub ahead of print 2012/12/29.
Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, et al. Prophylaxis with sirolimus and tacrolimus +/− antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2011;17:916–22. https://doi.org/10.1016/j.bbmt.2010.09.017. e-pub ahead of print 2010/10/12.
Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906–12. https://doi.org/10.1038/bmt.2016.130. e-pub ahead of print 2016/05/18.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a comprting risk. J Am Stat Assoc. 1999;94:496–509.
Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transpl. 2010;45:1388–95. https://doi.org/10.1038/bmt.2009.359. e-pub ahead of print 2010/01/12.
Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transpl. 2019;25:1271–80. https://doi.org/10.1016/j.bbmt.2019.02.018. e-pub ahead of print 2019/02/25.
Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40:378–85. https://doi.org/10.1016/j.clinre.2016.01.006. e-pub ahead of print 2016/04/04.
Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003;17:63–70. https://doi.org/10.1016/s0268-960x(03)00002-x. e-pub ahead of print 2003/03/19.
Zhang Y, Yan Y, Song B. Noninvasive imaging diagnosis of sinusoidal obstruction syndrome: a pictorial review. Insights Imaging. 2019;10:110 https://doi.org/10.1186/s13244-019-0791-x. e-pub ahead of print 2019/11/22.
Carmona A, Diaz-Ricart M, Palomo M, Molina P, Pino M, Rovira M, et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transpl. 2013;19:1439–45. https://doi.org/10.1016/j.bbmt.2013.07.001. e-pub ahead of print 2013/07/13.
Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transpl. 2010;16:1180–5. https://doi.org/10.1016/j.bbmt.2010.02.016. e-pub ahead of print 2010/02/27.
Strouse C, Zhang Y, Zhang M-J, DiGilio A, Lee SJ, Ramanathan M, et al. Stratification of allogeneic hematopoietic cell transplant patients by risk of developing veno-occlusive disease: a model for assigning a risk score. Biol Blood Marrow Transplant. 2017;23:S302–S303. https://doi.org/10.1016/j.bbmt.2016.12.221.
Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, Horowitz MM, et al. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transpl. 2018;24:2072–80. https://doi.org/10.1016/j.bbmt.2018.06.013. e-pub ahead of print 2018/06/22.
Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H, et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transpl. 2000;26:881–6. https://doi.org/10.1038/sj.bmt.1702624. e-pub ahead of print 2000/11/18.
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, et al. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:137–44. https://doi.org/10.1016/j.bbmt.2018.07.039. e-pub ahead of print 2018/08/07.
Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328–35. https://doi.org/10.2133/dmpk.22.328. e-pub ahead of print 2007/10/30.
Miriuka SG, Rao V, Peterson M, Tumiati L, Delgado DH, Mohan R, et al. mTOR inhibition induces endothelial progenitor cell death. Am J Transpl. 2006;6:2069–79. https://doi.org/10.1111/j.1600-6143.2006.01433.x. e-pub ahead of print 2006/06/27.
Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403–9. https://doi.org/10.1038/bmt.2015.283. e-pub ahead of print 2015/11/26.
Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, et al. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2017;52:592–9. https://doi.org/10.1038/bmt.2016.302. e-pub ahead of print 2017/01/17.
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4:e387–e398. https://doi.org/10.1016/s2352-3026(17)30103-5. e-pub ahead of print 2017/07/09.
Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016;44:61–64. https://doi.org/10.1016/j.leukres.2016.03.004. e-pub ahead of print 2016/04/01.
McDonald GB, Freston JW, Boyer JL, DeLeve LD. Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (inotuzumab ozogamicin). Hepatology. 2019;69:831–44. https://doi.org/10.1002/hep.30222. e-pub ahead of print 2018/08/19.
Schechter T, Perez-Albuerne E, Lin TF, Irwin MS, Essa M, Desai AV, et al. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. Bone Marrow Transpl. 2018. https://doi.org/10.1038/s41409-018-0298-y. e-pub ahead of print 2018/09/06.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Agrawal, V., Ranganath, P., Ervin, K.D. et al. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome. Bone Marrow Transplant 56, 121–128 (2021). https://doi.org/10.1038/s41409-020-0987-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0987-1